Thursday, May 12, 2016
CONTINENTAL BREAKFAST
07:00 - 08:00  
Introduction
08:00 - 08:15

Introduction to the Day’s Proceedings

Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada

William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada

SESSION 5:
08:15 - 09:45

Prevention of HBOC

CHAIR: Steven Narod, MD, FRCPC, Canada Research Chair in Breast Cancer, Women’s College Research Institute/University of Toronto, Toronto, ON, Canada

The effect of preventive oophorectomy on breast cancer risk

Matti Rookus, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands

Reducing cancer-related mortality in BRCA1/2 mutation carriers

Steven Narod, MD, FRCPC, Canada Research Chair in Breast Cancer, Women’s College Research Institute/University of Toronto, Toronto, ON, Canada

Proffered Paper 1 : BRCA population screening in unaffected Ashkenazi Jewish women: a randomized controlled trial of different pre-test strategies

Ephrat Levy-Lahad, MD, Medical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel

Proffered Paper 2 : Racial disparities in BRCA testing and surgical risk management uptake among young breast cancer survivors

Tuya Pal, MDCM, Cancer Epidemiology and Internal Medicine, Moffitt Cancer Center, Tampa, FL, USA

Proffered Paper 3 : Quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer

Yeh Chen Lee, BMedSci, MBBS, Division of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia

Question and discussion period (all speakers)

BREAK
09:45 - 10:15  
SESSION 6:
10:15 - 11:45

Treatment of HBOC

CHAIR: Mark Robson, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Treatment of hereditary breast and ovarian cancer with PARP inhibitors: an update

Mark Robson, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Assessing the role for platinum, taxanes and other chemotherapeutic agents in the treatment of BRCA-related breast cancer

Andrew Tutt, MB, ChB, PhD, MRCP, FRCR, The Breakthrough Toby Robins Breast Cancer Research Centre, London, UK

Proffered Paper 1 : Immunogenicity of BRCA1/2-mutated ovarian cancer: Implications for prognosis and therapy

Panagiotis Konstantinopoulos, MD, PhD, Gynecologic Oncology Program, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Proffered Paper 2 : Rapid genetic testing for BRCA1 and BRCA2 at the time of breast cancer diagnosis: the effects on treatment choices and psychosocial functioning

Kelly Metcalfe, RN, PhD, Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada

Proffered Paper 3 : The role of salpingectomy in the prevention of ovarian cancer in BRCA1/2 mutation carriers: a model to optimize risk communication

Marline Harmsen, MD, Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands

Question and discussion period (all speakers)

LUNCH - with guest speaker
11:45 - 13:15  


Optimizing BRCA testing processes in Canada

Laurie Elit, MD, MSc, FRCCS(C), Professor, Department of Obstetrics and Gynecology, McMaster University; Division head, Gynecologic Oncology, Juravinski Hospital and Cancer Centre, Hamilton, ON, Canada

An overview of the current BRCA testing landscape in Canada, highlighting some of the issues in regional centres and their approaches toward optimizing the testing and counselling process.

    Made possible through a restricted educational grant from AstraZeneca
SESSION 7:
13:15 - 14:45

New challenges in genetic counseling in the era of panel testing

CHAIR: Wendy McKinnon, MS, CGC, Familial Cancer Program, University of Vermont Cancer Center, Burlington, VT, USA

Issues facing young women with breast cancer who undergo a panel test

Lisa Madlensky, PhD, Family Cancer Genetics Program, University of California, San Diego, CA, USA

Genetic counseling models that differ from the standard approach

Jill Stopfer, MS, CGC, Dana Farber Cancer Institute, Boston, MA, USA

Proffered Paper 1 : Panel testing with a diverse low-income, limited-English-proficient population in the USA

Galen Joseph, PhD, Department of Anthropology, History & Social Medicine, & Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA

Proffered Paper 2 : Incorporating truncating variants in PALB2, CHEK2 and ATM into the BOADICEA breast cancer risk model

Antonis Antoniou, PhD, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

Proffered Paper 3 : Use of multiple SNP testing to predict breast cancer risk in a familial screening clinic

Elaine Harkness, PhD, Centre for Imaging Sciences, Institute for Population Health, University of Manchester, Manchester, UK

Question and discussion period (all speakers)

BREAK
14:45 - 15:15  
SESSION 8:
15:15 - 16:45

Special Interest Groups (SIGs)

Moderated interactive discussions with the aim of fostering bilateral knowledge transfer

Participants may attend one of the following concurrent SIGs:

SIG 1:

Panels: Mutations and VUS: Bring your own cases

Gareth Evans, MB, BS, MD, FRCP, St. Mary’s Hospital, Manchester, UK;

Lisa Madlensky, PhD, Family Cancer Genetics Program, University of California, San Diego, CA, USA;

Marc Tischkowitz, MD, PhD, University of Cambridge, Cambridge, UK

SIG 2:

NGS – beyond the basics and into the nitty gritty

Katherine Nathanson, MD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;

Jorge Reis-Filho, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

SIG 3:

Prostate and Pancreas cancer in high-risk families – Prevention, early diagnosis and treatment

Robert Bristow, PhD, MD, FRCPC, University Health Network-Princess Margaret Hospital, Toronto, ON, Canada;

George Zogopoulos, MD, PhD, McGill University, Montréal, QC, Canada

SIG 4:

Next-generation genetic counseling: Effective tools for promoting risk management adherence & psychosocial adjustment

Karen Hurley, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA;

Wendy McKinnon, MS, CGC, Familial Cancer Program, University of Vermont Cancer Center, Burlington, VT, USA

POSTER SESSION 2
16:45 - 18:30